As studies show that at least 40% of global dementia cases are linked to modifiable lifestyle, cardiometabolic and environmental risk factors, dementia might be prevented or delayed with targeted, multidomain set of intervention measures. The FINGER intervention model - Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (PI Prof Kivipelto, ClinicalTrials.gov: NCT01041989) - is a unique, large, long-term trial (RCT) showing the cognitive benefits of a multidomain intervention, which combined healthy diet, exercise, cognitive training, social activities, and vascular/metabolic risk management. The trial reported cognitive improvement in at-risk older adults, including individuals with genetic susceptibility for Alzheimer´s disease (AD), and yielded positive changes in several AD-related biomarkers. Findings from the 2-year multidomain intervention (plus regular follow-ups over 11-years) comprised additional health benefits, including reduced risk of physical decline, i.e., development of disability, reduced occurrence of other chronic diseases, especially multimorbidity, and cardiovascular diseases. The FINGER intervention reduced hospitalization and was cost-effective.

The World-Wide FINGERS global network of multidomain RCTs was launched in 2017 (currently 60+ countries, PI Prof Kivipelto), and the FINGERS Brain Health Institute (FBHI) was founded in 2019 to advance AD and dementia prevention through development, adaptation, and global implementation of the FINGER model. On May 2023, ADDF and FBHI signed a Memorandum of Understanding to cooperate in expanding and synergizing efforts to achieve and implement precision prevention for AD and dementia in ageing populations.

The ADDF-FBHI partnership aims to advance early detection and therapeutics for AD and dementia, by i) Leveraging a multisite clinical-platform to test novel combined therapies (pharmacological/non-pharmacological), ii) Identifying easily-available, accurate markers enabling early detection of AD and associated neuropathologies, dementia risk, and prevention potential, iii) Harnessing digital solutions to scale and personalize preventive interventions, iv) Enhancing scientific dissemination to key stakeholders to facilitate implementation of precision prevention of AD and dementia.